Overview

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Status:
Active, not recruiting
Trial end date:
2022-01-28
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc.
Collaborator:
Merck KGaA, Darmstadt, Germany
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Docetaxel
Gemcitabine
Paclitaxel
Pemetrexed